Flatiron Health, together with the oncology-focused company Via Oncology, recently announced that patients with several types of cancer can now have access to the tool Via Pathways, which is fully embedded in Flatiron Health’s OncoEMR. Mesothelioma is one of the cancers considered.
OncoEMR is an electronic health record (EHR) that enables cancer care providers to manage and document the whole treatment process within a single cloud-based system. As part of OncoEMR, Via Pathways is a tool to monitor the continuum of cancer care, including workup, diagnostics, treatments, symptom management, survivorship and advance care planning.
The licensing is now available for patients suffering from certain cancers, including mesothelioma, multiple myeloma, non-small-cell and small-cell lung cancer, breast cancer, and prostate, colon, and rectal cancers. Additional tumor types will have their Via Pathways version available throughout the course of 2016.
“Using Via Pathways directly in OncoEMR brings real time evidence-based decision support to our clinicians at the point of care. Additionally, this fully integrated model saves time by avoiding duplicate data entry,” Northwest Medical Specialties’ Frank Senecal, M.D., said in a press release. Northwest Medical Specialties was the first to provide Via Pathways embedded in OncoEMR.
The Flatiron Health and Via Oncology partnership allows OncoEMR providers, who are licensing Via Pathways, to easily identify proven regimens within their clinical workflow, report on pathways adherence directly, and use them to participate in value-based reimbursement models. Now, OncoEMR is the single cloud-based medical oncology EHR to enable providers to choose their pathways and medical content of preference.
“By leveraging PathBuildR, our dynamic content authoring tool, and Flatiron Health’s industry-leading cloud-based software platform, our mutual customers can stay up to date with the most current Via Pathways,” said Via Oncology President and CEO Kathy Lokay.
“We heard from providers across the country that there was a desire to bring pathways directly into the EHR,” said Flatiron Health’s senior vice president of clinical oncology, Robert J. Green, M.D. “As a result, our engineering and clinical teams developed software to fully embed the Via Pathways decision support tool within OncoEMR and help providers improve efficiency and standardize treatment selection across patients and diseases. By utilizing Via Pathways in OncoEMR, providers have a mechanism to demonstrate adherence to evidence-based care and participate in value-based care programs.”
